KR20250162926A - 피라졸일-아미노-피리미딘일 유도체의 벤즈아미드, 이의 조성물 및 방법 - Google Patents

피라졸일-아미노-피리미딘일 유도체의 벤즈아미드, 이의 조성물 및 방법

Info

Publication number
KR20250162926A
KR20250162926A KR1020257036502A KR20257036502A KR20250162926A KR 20250162926 A KR20250162926 A KR 20250162926A KR 1020257036502 A KR1020257036502 A KR 1020257036502A KR 20257036502 A KR20257036502 A KR 20257036502A KR 20250162926 A KR20250162926 A KR 20250162926A
Authority
KR
South Korea
Prior art keywords
mmol
compound
amino
pyrazol
yield
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257036502A
Other languages
English (en)
Korean (ko)
Inventor
자오귀 완
마이클 로렌스 바즈케즈
샤오동 리
Original Assignee
링크 파마슈티컬스 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 링크 파마슈티컬스 컴퍼니 리미티드 filed Critical 링크 파마슈티컬스 컴퍼니 리미티드
Publication of KR20250162926A publication Critical patent/KR20250162926A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020257036502A 2018-12-14 2019-12-16 피라졸일-아미노-피리미딘일 유도체의 벤즈아미드, 이의 조성물 및 방법 Pending KR20250162926A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/121165 2018-12-14
PCT/CN2018/121165 WO2020118683A1 (en) 2018-12-14 2018-12-14 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
PCT/CN2019/125552 WO2020119819A1 (en) 2018-12-14 2019-12-16 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
KR1020217019621A KR102881668B1 (ko) 2018-12-14 2019-12-16 피라졸일-아미노-피리미딘일 유도체의 벤즈아미드, 이의 조성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217019621A Division KR102881668B1 (ko) 2018-12-14 2019-12-16 피라졸일-아미노-피리미딘일 유도체의 벤즈아미드, 이의 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20250162926A true KR20250162926A (ko) 2025-11-19

Family

ID=71076270

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257036502A Pending KR20250162926A (ko) 2018-12-14 2019-12-16 피라졸일-아미노-피리미딘일 유도체의 벤즈아미드, 이의 조성물 및 방법
KR1020217019621A Active KR102881668B1 (ko) 2018-12-14 2019-12-16 피라졸일-아미노-피리미딘일 유도체의 벤즈아미드, 이의 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217019621A Active KR102881668B1 (ko) 2018-12-14 2019-12-16 피라졸일-아미노-피리미딘일 유도체의 벤즈아미드, 이의 조성물 및 방법

Country Status (14)

Country Link
US (6) US12421213B2 (https=)
EP (1) EP3877381A4 (https=)
JP (3) JP7459094B2 (https=)
KR (2) KR20250162926A (https=)
CN (7) CN119118999A (https=)
AU (3) AU2019399939B2 (https=)
BR (1) BR112021011147A2 (https=)
CA (3) CA3122872A1 (https=)
EA (1) EA202191188A1 (https=)
IL (3) IL314086A (https=)
MX (3) MX2021006866A (https=)
SG (1) SG11202105730TA (https=)
TW (3) TWI889397B (https=)
WO (2) WO2020118683A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
CN112661655B (zh) * 2020-12-29 2022-02-18 江苏云朴医药新材料科技有限公司 一种1-氨甲基-1-环丙醇类化合物及其合成方法
EP4577535A1 (en) * 2022-08-22 2025-07-02 Hangzhou Highlightll Pharmaceutical Co., Ltd. Jak1/jak2/tyk2 inhibitors for topical treatment of dermatological diseases
CN115572269B (zh) * 2022-10-08 2024-05-17 广州大学 一种n-三氟异丙基唑类和吲哚化合物及其制备方法
WO2023151724A1 (zh) * 2023-05-19 2023-08-17 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用
CN116751191B (zh) * 2023-05-19 2025-09-16 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用
WO2024239282A1 (zh) 2023-05-24 2024-11-28 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用
CN116983312B (zh) * 2023-05-24 2024-07-05 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用
TW202545932A (zh) * 2024-01-26 2025-12-01 大陸商凌科藥業(杭州)有限公司 一種吡唑基-胺基-嘧啶基衍生物的苯甲醯胺的晶型、製備方法及應用
WO2025157231A1 (zh) * 2024-01-26 2025-07-31 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的苯甲酰胺的晶型、制备方法及应用
WO2025256636A1 (zh) * 2024-06-13 2025-12-18 凌科药业(杭州)有限公司 含氮化合物及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
WO2007005644A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
AU2006275702A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
CA2616383C (en) 2005-07-29 2015-06-09 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US8481538B2 (en) * 2006-09-18 2013-07-09 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of c-Met and uses thereof
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
WO2009064835A1 (en) * 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
AU2011328237A1 (en) * 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
WO2012143320A1 (en) * 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
CN103781780B (zh) * 2011-07-28 2015-11-25 赛尔佐姆有限公司 作为jak抑制剂的杂环基嘧啶类似物
DE102011112978A1 (de) * 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
KR101361149B1 (ko) * 2012-07-17 2014-02-24 전남대학교산학협력단 가뭄 스트레스 저항성 관련 유전자 및 형질전환 식물체
EP3080103B9 (en) * 2013-12-11 2018-09-19 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CN106349224A (zh) * 2016-08-03 2017-01-25 山东大学 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用
CN108864057B (zh) * 2017-05-16 2020-03-31 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
WO2020206588A1 (en) * 2019-04-08 2020-10-15 Lynk Pharmaceuticals Co., Ltd. Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN110330484B (zh) * 2019-07-18 2022-08-26 中国药科大学 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物

Also Published As

Publication number Publication date
IL283968A (en) 2021-07-29
BR112021011147A2 (pt) 2021-08-31
AU2024201128A1 (en) 2024-03-14
JP2022510925A (ja) 2022-01-28
US20220298144A1 (en) 2022-09-22
AU2024201125B2 (en) 2025-03-06
MX2021006866A (es) 2021-11-17
WO2020119819A1 (en) 2020-06-18
CN118903141A (zh) 2024-11-08
TW202440559A (zh) 2024-10-16
KR20210125983A (ko) 2021-10-19
US20230416235A1 (en) 2023-12-28
IL314086A (en) 2024-09-01
AU2019399939B2 (en) 2024-07-11
JP2024089673A (ja) 2024-07-03
AU2024201125A1 (en) 2024-03-14
CN113227074A (zh) 2021-08-06
CN118290403A (zh) 2024-07-05
JP7802105B2 (ja) 2026-01-19
US12098142B2 (en) 2024-09-24
TW202440558A (zh) 2024-10-16
TW202039474A (zh) 2020-11-01
AU2024201128B2 (en) 2025-03-06
US20240083881A1 (en) 2024-03-14
EP3877381A1 (en) 2021-09-15
US12030870B2 (en) 2024-07-09
CN113227074B (zh) 2024-08-16
MX2024005747A (es) 2024-05-28
EA202191188A1 (ru) 2021-11-29
CN118388457A (zh) 2024-07-26
MX2024005744A (es) 2024-05-28
EP3877381A4 (en) 2022-08-24
KR102881668B1 (ko) 2025-11-04
JP2024088646A (ja) 2024-07-02
CA3122872A1 (en) 2020-06-18
CN118955477A (zh) 2024-11-15
IL283968B2 (en) 2025-09-01
US20250115586A1 (en) 2025-04-10
US11981663B2 (en) 2024-05-14
SG11202105730TA (en) 2021-06-29
CN119118999A (zh) 2024-12-13
US12595253B2 (en) 2026-04-07
US20240025882A1 (en) 2024-01-25
TWI866940B (zh) 2024-12-21
CA3230060A1 (en) 2020-06-18
JP7802106B2 (ja) 2026-01-19
US12421213B2 (en) 2025-09-23
US20230002362A1 (en) 2023-01-05
TWI889397B (zh) 2025-07-01
CA3230071A1 (en) 2020-06-18
JP7459094B2 (ja) 2024-04-01
IL314084A (en) 2024-09-01
CN118903142A (zh) 2024-11-08
AU2019399939A1 (en) 2021-06-24
TWI889396B (zh) 2025-07-01
IL283968B1 (en) 2025-05-01
WO2020118683A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
KR102881668B1 (ko) 피라졸일-아미노-피리미딘일 유도체의 벤즈아미드, 이의 조성물 및 방법
HK40113561A (zh) 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
HK40119082A (zh) 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其组合物和方法
HK40113562A (zh) 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
HK40118199A (zh) 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其组合物和方法
HK40119081A (zh) 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其组合物和方法
HK40118201A (zh) 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其组合物和方法
HK40057223A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
HK40057223B (zh) 吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其组合物和方法
BR122024013896A2 (pt) Compostos de benzamidas derivados de pirazolil-amino-pirimidinila e seus usos, composição farmacêutica dos mesmos, e forma de dosagem unitária compreendendo a mesma
EA048017B1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902